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Identifying inhibitors of 
the Leishmania inositol 
phosphorylceramide synthase 
with antiprotozoal activity using a 
yeast-based assay and ultra-high 
throughput screening platform
Jennifer L. Norcliffe1,2, John G. Mina1,2, Emilio Alvarez3, Juan Cantizani3, Francisco de Dios-
Anton3, Gonzalo Colmenarejo  3,4, Silva Gonzalez-Del Valle3, Maria Marco3, José M. Fiandor3, 
Julio J. Martin3, Patrick G. Steel2 & Paul W. Denny  1
Leishmaniasis is a Neglected Tropical Disease caused by the insect-vector borne protozoan parasite, 
Leishmania species. Infection affects millions of the world’s poorest, however vaccines are absent and 
drug therapy limited. Recently, public-private partnerships have developed to identify new modes of 
controlling leishmaniasis. Drug discovery is a significant part of these efforts and here we describe the 
development and utilization of a novel assay to identify antiprotozoal inhibitors of the Leishmania 
enzyme, inositol phosphorylceramide (IPC) synthase. IPC synthase is a membrane-bound protein with 
multiple transmembrane domains, meaning that a conventional in vitro assay using purified protein in 
solution is highly challenging. Therefore, we utilized Saccharomyces cerevisiae as a vehicle to facilitate 
ultra-high throughput screening of 1.8 million compounds. Antileishmanial benzazepanes were 
identified and shown to inhibit the enzyme at nanomolar concentrations. Further chemistry produced a 
benzazepane that demonstrated potent and specific inhibition of IPC synthase in the Leishmania cell.
The Neglected Tropical Disease (NTD) leishmaniasis is endemic in over 90 countries worldwide, affecting 
approximately 12 million people per year with 350 million people living at risk of disease. The causative agent, 
Leishmania species, are sandfly borne kinetoplastid protozoan parasites1.
A vaccine to prevent leishmaniasis is not currently available and treatment relies entirely on a limited number 
of chemotherapeutics with, in the most part, unclear modes of action2. For example, cutaneous leishmaniasis (CL, 
e.g. caused by L. major) therapy largely relies on two pentavalent antimonials, sodium stibogluconate (Pentostam) 
and meglumine antimoniate (Glucantime)3,4. Despite their problems, including severe side-effects such as car-
diotoxicity and the requirement for parenteral administration5, Pentostam and Glucantime have been in clinical 
use for more than 70 years6. The treatment options for visceral leishmaniasis (VL, Kala-Azar; largely caused by L. 
donovani) suffer from similar problems, with antimonial therapy still widely employed3,4. In addition, resistance 
to these drugs is rising and threatening their continued use in the treatment of leishmaniasis7. Amphotericin B 
(Fungizone) has also been used in the treatment of both CL and VL8. However, this is also associated with severe 
side-effects, and must be administered parentally9. Miltefosine, is the only orally available antileishmanial and 
has been used to treat VL in India since 2002, however, this antineoplastic compound also exhibits teratogenicity 
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and resistance is increasingly apparent10. Therefore, the current elimination programme in South Asia relies upon 
liposomal amphotericin B administered as a single injection. However, whilst effective and less toxic than the 
non-liposomal formulation, treatment failure and post-Kala-Azar dermal leishmaniasis (PKDL) may preclude 
elimination11.
With these severe problems in the treatment and control of both CL and VL, it is recognized that new 
antileishmanial targets and drugs need to be identified. High throughput screening (HTS) is a vital component of 
drug discovery and can be carried out using either in vitro assays against validated targets or in phenotypic assays 
against the parasite itself12,13. Recent high content phenotypic screening across the pathogenic kinetoplastids 
gave a disappointingly low number of novel potent hits against Leishmania donovani when compared with the 
related parasites Trypanosoma brucei and T. cruzi14. This demonstrated the importance of target-based screening 
for antileishmanial discovery to access to novel chemical space and new modes of action which may overcome 
resistance and be compatible in combination therapies.
In contrast to mammalian cells, where the predominant complex sphingolipid is sphingomyelin (SM), fungi, 
plants and some protozoa synthesize inositol phosphorylceramide (IPC)15,16. The fungal IPC synthase (AUR1p) 
has long been established as a drug target for pathogenic fungi17. Similarly, the Leishmania orthologue, and those 
from the pathogenic Trypanosoma species, have been suggested to be ideal, non-mammalian, targets for the 
development of new, less toxic, antiprotozoals15,18–20. Furthermore, systems biology studies have reinforced the 
status of the Leishmania enzyme as a putative target for drug discovery programmes21. However, as an integral 
membrane protein with 6 transmembrane domains, and lipid substrates (phosphatidylinositol and ceramide) and 
products (diacylglycerol and IPC), formatting the Leishmania IPC synthase into a conventional in vitro assay plat-
form is challenging22. Therefore, utilizing the ability of the kinetoplastid enzyme to complement for the absence of 
the Saccharomyces cerevisiae orthologue AUR1p23, here we describe the development and formatting of a robust 
yeast-based ultra-HTS (uHTS) assay platform. This was then utilized, in the largest effort of its type, to screen a 
high content (1.8 M) compound library for specific Leishmania IPC synthase inhibitors. 500 potent and specific 
such compounds were identified; these were then reduced to 211 following clustering to remove structural repli-
cates. Following screening against mammalian-stage axenic amastigote L. donovani, 25 of these compounds were 
selected on the basis of potency, selectivity and physicochemical properties. These hits were then reduced to five 
following further screening of L. donovani infected macrophages. From these, one pair of structurally related 
compounds, the benzazepanes, was selected for further analyses. Importantly, these compounds demonstrated 
sub micro-molar activity against the enzyme target in a secondary in vitro assay and selectivity for the enzyme 
in cellulo when using an available L. major sphingolipid mutant24. This work demonstrated the tractability of 
yeast-vehicles for uHTS, with the identification of the benzazepanes as potential antileishmanials with specific 
inhibitory activity against IPC synthase.
Results
Design and validation of a robust Leishmania IPC synthase assay for uHTS. HTS campaigns pre-
dominantly rely on two approaches: (i) in vitro target-directed screening using biochemical assays; (ii) cell-based 
phenotypic screening which takes no account of the target. Both of these approaches have significant limitations, 
such as the production of soluble protein and a lack of cellular context for biochemical assays, and the problems 
of process redundancy in cells used for phenotypic screening13. Furthermore, both can be difficult to miniaturize 
and expensive to utilize for uHTS. With these problems in mind, yeast-based systems have been utilized to pro-
vide cost-effective, target-directed, screening platforms for protein targets within a eukaryotic cellular context13. 
Recently, this approach has been adopted for antiprotozoal drug discovery12,25,26.
The transmembrane nature of the target Leishmania IPC synthase, and the hydrophobicity of the lipid sub-
strates and products, rendered it challenging to develop a uHTS biochemical assay18,19,22. However, given that the 
enzyme has been shown to complement an auxotrophic Saccharomyces cerevisiae mutant18 the development of 
yeast-based screening platform was considered tractable. To develop a robust assay suitable for uHTS, rather than 
the previously utilized auxotrophic mutant18, a strain of S. cerevisiae completely lacking the yeast IPC synthase, 
AUR1p, was selected as the vehicle (a kind gift from Teresa Dunn, Uniformed Services University)27. This strain is 
reliant on the expression of essential AUR1p from a uracil selectable expression plasmid (pRS316-URA-AUR1)27. 
Transforming these with the plasmid pESC-LEU (Agilent) harbouring the L. major IPC synthase (LmjFIPCS) 
or AUR1p under the control of a galactose promotor, allowed for curing the yeast of pRS316-URA-AUR1 using 
the pyrimidine analogue 5-fluoro-orotic acid (5-FOA) and the selection of a strain dependant on the galactose 
inducible expression of LmjFIPCS (Fig. 1). The yeast dependant on either LmjFIPCS or AUR1p expression were 
then used to format an LmjFIPCS assay suitable for uHTS.
Exploiting the fact that growing yeast secretes exo-β-glucanase, which, as well as modifying the cell wall, can 
also hydrolyse non-fluorescent fluorescein di-(β-D-glucopyranoside) (FDGlu) to release fluorescein, an assay was 
developed in which cell growth was monitored by fluorescent output28. The optimal concentrations of galactose 
(0.1%), starter culture (OD600 0.063) and FDGlu (10 μM) were established in 96- and 384-well formats incubated 
at 30 °C for 24 hours. The assay was then miniaturized into a 1536-well format, the most appropriate positive con-
trol (cycloheximide) selected and the robustness of the platform indicated by Z’ values >0.529. Screening using 
a GSK standard set of (9766) compounds further validated the assay, established inhibition threshold values and 
indicated a hit-rate of 1.07%.
Identification of selective and potent inhibitors. Taking the robust 1536-well format assay developed, 
a primary uHTS screening was conducted using the 1.8 million compound GSK library against the LmjFIPCS 
dependent yeast. Given the hit-rate of 1.07% with the standard set approximately 19000 hits were anticipated. 
Initially this expectation was not reached, however reducing the inhibition threshold to capture small (≤300 Da 
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molecular weight), polar (cLogP ≤ 3) ‘drug-like’ compounds with lower efficacy, led to the identification of 19669 
hits. The mean Z’ for the screen was 0.70, demonstrating the platform to be robust.
At this stage, the primary screen, it was unclear whether the hit compounds inhibited the LmjFIPCS enzyme 
or (an)other essential process(es) within the yeast vehicle. Therefore, a counter screen was performed against the 
yeast dependant on AUR1p expression at a single compound concentration of 10 μM. In parallel, a confirmatory 
screen against the LmjFIPCS dependent yeast was performed at the same concentration. After calculation of the 
inhibition thresholds for each strain, those compounds demonstrating activity above the LmjFIPCS threshold 
but below AUR1p threshold were selected. In addition, to avoid loss of highly potent compounds, those demon-
strating >80% inhibition of the LmjFIPCS dependent yeast were retained whatever the response against AUR1p 
dependent yeast.
As a result of this process, 4166 compounds were progressed further for dose response analyses. Using the 
optimized assay conditions, these compounds were screened against the yeast dependant on either LmjFIPCS 
or AUR1p expression at 11 concentrations between 100 μM to 1.7 nM. From these data, the −logIC50 (pIC50) 
molar unit values of each compound were calculated against each strain and the data plotted (Fig. 2). This allowed 
analyses of both potency and selectivity, with 500 compounds demonstrating potent activity against LmjFIPCS 
dependant yeast, pIC50 ≥ 5 (IC50 ≤ 10 μM), and good selectivity when compared to AUR1p dependant yeast, 
Figure 1. Generation of yeast strains for uHTS assay. Yeast lacking AUR1p completed by galactose dependent 
expression of AUR1p (α ade−.lys−.leu−.Δaur1−.pESC-LEU_AUR1) or LmjFIPCS (α ade−.lys−.leu−.Δaur1−.
pESC-LEU_LmjFIPCS) grown on selective media with either glucose (A) or galactose (B). Expression of both 
AUR1p and LmjFIPCS rescues growth of the mutant S. cerevisiae.
Figure 2. The dose response (−logIC50 M [pIC50]) of the initially identified 4166 selective hit compounds. Yeast 
dependent on Leishmania IPC synthase activity (LmjFIPCS) against yeast dependent on AUR1p expression. The 
inset shows the colour key for compound selectivity (logSI [pSI] where SI is Selectivity Index). 500 hits with a 
pSI > 1.50 were selected for further analyses (orange, turquoise and brown).
www.nature.com/scientificreports/
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pSI ≥ 1.5 (logSI [pIC50 LmjFIPCS - pIC50 AUR1], where SI is Selectivity Index). This represented a hit rate of 
0.0063% for the identification of potent and selective hits against LmjFIPCS.
These 500 compounds were subsequently clustered using a sphere exclusion algorithm30. Briefly, a fingerprint 
for each hit was compared to every other molecule in the set and compounds demonstrating significant similarity 
( > 0.85 on a scale of 0–1) were sorted into clusters. Two representatives from each cluster plus all singletons, 211 
compounds, were taken forward for further analyses.
Cell-based screening of identified compounds. To establish the antileishmanial activity of the 211 
selected hits, they were screened against L. donovani axenic amastigotes (the mammalian, pathogenic form) in a 
dose response assay with 11 compound concentrations between 50 μM and 0.85 nM. The data revealed 70 com-
pounds with a calculated pIC50 ≥ 5 (IC50 ≤ 10 μM; Fig. 3A; SI Table).
Following a screen against HepG2 cells for mammalian cytotoxicity (11 compound concentrations between 
100 μM and 1.7 nM), comparing these data with that for the 70 Leishmania hits allowed identification of selective 
antileishmanial compounds with pSI ≥ 1 (SI ≥ 10); 49 compounds fulfilled these criteria (Fig. 3B). Following a 
further screen based on the predicted physicochemical properties of these 49 compounds, those compounds 
showing a Property Forecast Index31 (PFI) ≤8 and ≤4 aromatic rings were selected (Fig. 3C; SI Table 1)). These 25 
compounds have relatively low molecular weights and high levels of hydrophilicity indicating they are likely to be 
soluble and favourable for development, and therefore were progressed to screening against L. donovani infected 
THP-1 macrophages, the truest representation of the pathogenic state available in vitro. The 25 compounds were 
screened in a dose response assay with 11 compound concentrations between 50 μM and 0.85 nM. Given the 
additional membrane barriers the compounds must cross to reach the intra-macrophage amastigotes, the fact 
that only 7 (out of 25) were completely ineffective while 10 of the remaining 18 active hits demonstrated activity at 
pIC50 ≥ 5 (IC50 ≤ 10 μM) was promising. Of these 10, 4 had a pSI with respect to the activity against THP-1 mac-
rophages of ≥1 (Fig. 3D; SI Table 1), another had a pSI of 0.99 and was also retained. Of these 5 hits (Fig. 4), the 
benzazepane compounds (1 and 2) were both active in the low μM range against intra-macrophage amastigotes, 
pIC50 5.5 and 5.7 respectively. The dithiophene compounds (3 and 4) exhibited similar levels of activity, pIC50 
5.7 and 5.9 respectively, however, the presence of the nitro group in this class was a concern given the link with 
toxicity issues32. Similarly, the singleton (5) possesses a nitro group. In light of the above, the benzazepanes were 
taken forward for further analyses in a secondary screening platform19,22.
Verification of the benzazepane mode of action. Utilizing the availability of an in-house designed 
and validated biochemical assay for LmjFIPCS19,22, following re-synthesis in the free-base form (Aptuit, Verona, 
Italy) the two benzazepane hits were biochemically analyzed in a dose response assay (8 compound concentra-
tions between 100 μM and 46 nM; Fig. 5). Whilst compound 2 was a modest inhibitor of LmjFIPCS (pIC50 5.2), 
compound 1 was a potent, sub μM, inhibitor of the enzyme (pIC50 6.8).
Figure 3. The triage of 211 clustered hits. (A) Dose response against axenic Leishmania donovani amastigotes, 
−logIC50 M (pIC50) ≥5 selected (70 active compounds; on or above green line); (B) Comparison of dose response 
values from (A) versus the 70 compounds selectivity (logSI [pSI] where SI is Selectivity Index) against human 
HepG2 cells, pSI ≥1 selected (49 non-toxic compounds; on or above green line); (C) Predicted Property Forecast 
Index31 (PFI) of these compounds against the number of aromatic rings, PFI ≤ 8 and aromatic rings ≤ 4 selected 
(25 small/hydrophobic compounds; on or within green lines); (D) Comparison of dose response values of these 
25 compounds for intra-macrophage Leishmania donovani amastigotes (InMac) versus the selectivity (pSI) 
against human THP-1 macrophages, the host, pSI ≥ 1 selected (5 selective compounds; on or within green lines).
www.nature.com/scientificreports/
5SCientifiC RepoRts |  (2018) 8:3938  | DOI:10.1038/s41598-018-22063-9
Figure 4. The 5 identified selective, non-toxic, hits. −logIC50 M (pIC50) and logSI (pSI, where SI is Selectivity 
Index) values for infected macrophage assay indicated.
Figure 5. In vitro activity against LmjFIPCS. Activity of compound 1 (red; −logIC50 M [pIC50] 6.8; 95% CI: 
7.0–6.5) and compound 2 (blue; pIC50 5.2; 95% CI: 5.5–4.9) against LmjFIPCS in vitro. Values are from at least 3 
independent experiments.
www.nature.com/scientificreports/
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However, whilst compound 1 was antiprotozoal and a potent IPC synthase inhibitor, it was unclear whether 
the mode of action was on-target. To analyze this further, the in-house availability of a sphingolipid mutant L. 
major (Δlcb2) was exploited. This line24 lacks serine palmitoyltransferase activity, and whilst LmjFIPCS is still 
present it is redundant in the absence of in situ substrate. Therefore, specific inhibitors of LmjFIPCS should be 
inactive against L. major Δlcb2. However, in a dose response assay, compound 1 demonstrated no significant 
difference in activity against both lines of L. major (pIC50 5.5 for wild type and Δlcb2: SI Fig. 1)). Therefore, it is 
likely that off-target activity has a role in the antileishmanial activity of this benzazepane.
Further synthetic efforts (Aptuit, Verona, Italy) led to the synthesis of compounds bearing the left-hand side 
of 1 and the right-hand side of 2 (compound 6) and vice versa (compound 7; Fig. 6A). Compound 6 lost activity 
against LmjFIPCS in the in vitro assay; however, compound 7 maintained a pIC50 7.2; although it did not achieve 
greater than approximately 60% inhibition even at higher concentrations (Fig. 6B). In addition, and importantly, 
compound 7 demonstrated selectivity for L. major wild type over the Δlcb2 mutant (pIC50 5.5 versus <5; Fig. 6C). 
The selectivity of compound 7 for the wild type parasite over a line with a redundant LmjFIPCS (Δlcb2), strongly 
supported a target-directed mode of action. Furthermore, compound 7 demonstrated considerably greater in 
cellulo inhibition of IPC synthase activity than compound 1, as determined by incorporation of BODIPY® FL 
C5-ceramide into IPC in the presence of the compounds (Fig. 7). Unfortunately, activity against intramacrophage 
L. donovani was lost, possibly due to a lack of compound transport to the site of action or intramacrophage sta-
bility. However, these data demonstrated that the efficacy of compound 7 against L. major is on-target inhibition 
of IPC synthase, thus supporting the status of LmjFIPCS as a drug target like its orthologues in the related trypa-
nosomatid pathogen, T. brucei20.
Discussion
The identification of leads for the discovery of new drugs for the Neglected Tropical Disease leishmaniasis is a recog-
nized priority2,6. To achieve this aim the development of strong industry-academia partnerships, bridging chemistry 
and biology, is vital23. Much of such collaborative efforts have employed HTS to identify antiprotozoal compounds, 
however high content phenotypic screening has produced a poor return of hits against Leishmania spp when 
Figure 6. The discovery of a selective inhibitor. (A) Synthesized chimeric compounds 6 and 7; (B) activity of 
compound 7 against LmjFIPCS in vitro (−logIC50 M [pIC50] 7.2; 95% CI: 7.8–6.9); (C) activity of compound 7 
against wild type Leishmania major (red; pIC50 5.5; 95% CI: 5.8–5.2) and the mutant, ΔLCB2 (blue; pIC50 < 5). 
Values are from at least 3 independent experiments.
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compared with the related Trypanosoma spp14. This demonstrated the central importance of target-based screening 
for the discovery of novel antileishmanial hits which represent new chemical entities with new modes of action.
The Leishmania IPC synthase has been previously identified as a putative drug target18,21, and more recent 
work has employed a modelling approach to identify coumarin derivatives as enzyme inhibitors with in vivo 
antileishmanial activity33,34. To search for new classes of Leishmania IPC synthase inhibitors, in a multidisci-
plinary public-private partnership, we developed a novel yeast-based assay to screen the 1.8 million entity GSK 
compound library against the protozoan enzyme. To the best of our knowledge, this work reports the largest 
yeast-based, target-directed assay undertaken to date against targets from any disease state.
5 non-toxic, antileishmanial compounds were identified (a hit rate of 0.00028%), 2 pairs and one singleton. On 
the basis of a lack of nitro groups the benzazepanes (compounds 1 and 2) were selected to take forward. Both of these 
demonstrated sub μM activity against axenic L. donovani amastigotes (pIC50, 7.6 and 6.4 for compounds 1 and 2 respec-
tively; SI Table), and low μM activity against L. donovani infected macrophages (pIC50, 5.5 and 5.7 for compounds 1 
and 2 respectively; SI Table). The activity of these compounds in cell based assays, when compared to other recently 
predicted Leishmania IPC synthase inhibitors33,34, was promising. These activity levels were similar to those seen for 
miltefosine, the only oral therapy for leishmaniasis but with an unclear mode of action2,35. However, they were one or 2 
orders of magnitude lower than those for amphotericin B, which functions through selective sterol binding2,35.
Importantly, both benzazepanes demonstrated activity against the Leishmania IPC synthase in vitro, with 
compound 1 particularly potent (pIC50 6.8). Despite these promising findings, this compound also demonstrated 
off-target activities in the parasite ( SI Fig.1). However, using a simple ‘mix and match’ approach a benzaze-
pane was identified that had enhanced potency against the enzyme in vitro (pIC50 7.2) and in cellulo (Fig. 7) and 
demonstrated more selective, on-target antileishmanial activity (Fig. 6).
In summary, this research demonstrated the tractability of yeast-based uHTS to identify inhibitors of chal-
lenging, membranous targets such as IPC synthase, which are on-target and specific. Furthermore, the ben-
zazepanes identified represent a new class of antileishmanial compounds with a new mode of action. Further 
development of these may lead to novel therapies for the Neglected Tropical Disease, leishmaniasis.
Methods
Yeast cell assay. The complete open reading frames of LmjFIPCS and AUR1p was amplified from genomic 
DNA using Phusion Flash PCR master mix (ThermoFisher) according to manufacturer’s guidelines. Primers 
were for T4 ligation of LmjFIPCS (F_BamHI cgcggatccATGACGAGTCACGTGACAGC and R_HindIII 
cccaagcttTTAGTGCTCAGGCAAAGCCGCCG) and In-Fusion cloning (Clontech) of AUR1 (F ctcactatag-
ggcccATGGCAAACC and R tccatgtcgacgcccTTAAGCCCTC). The open reading frames were subsequently 
cloned into the pESC-LEU vector (Agilent) and verified by sequence analyses, creating pESC-LEU_ LmjFIPCS 
and pESC-LEU_AUR1. In this vector, expression of the open reading frame was under the control of a galac-
tose promoter. pESC-LEU_ LmjFIPCS and pESC-LEU_AUR1 were subsequently transformed into S. cerevi-
siae strain α ade−.lys−.leu−.Δaur1−.pRS316.URA+.ScAUR1+27 as previously described18–20 and selected on SD 
-TRP -URA -LEU agar (0·17% Bacto Yeast Nitrogen Base, 0·5% ammonium sulphate, 2% glucose, containing 
the appropriate nutritional supplements) at 30 °C. Clones were then ‘cured’ of the pRS316-URA plasmid by 
selection on SGR -TRP –LEU +FOA agar (0·17% Bacto Yeast Nitrogen Base, 0·5% ammonium sulphate, 0.1% 
Figure 7. In cellulo activity against LmjFIPCS. Compound 7 demonstrated a greater activity against in cellulo 
LmjFIPCS than compound 1. L. major ΔLCB2 treated with 10 μM of compound prior to metabolic labelling 
with BODIPY FL C5-ceramide. Inhibition of the incorporation of label into IPC was measured following 
HPTLC in comparison with a control (vehicle treated). Values are from 3 independent experiments. P = 0.006 
in students’ t-test indicating the difference is significant (**≤ 0.01).
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galactose, 1% raffinose, 0.1% 5-Fluoroorotic Acid Monohydrate (FOA) containing the appropriate nutritional 
supplements) at 30 °C, creating α ade−.lys−.leu−.Δaur1−.pESC-LEU_LmjFIPCS and α ade−.lys−.leu−.Δaur1−.
pESC-LEU_AUR1. Following validation by PCR and propagation in SGR -TRP –LEU, frozen stocks of both 
yeast lines were created (OD600 = 10). 10 µM FDGlu and α ade−.lys−.leu−.Δaur1−.pESC-LEU_LmjFIPCS or 
α ade−.lys−.leu−.Δaur1−.pESC-LEU_AUR1 (defrosted on ice) at OD600 = 0.0625 in SGR -TRP -LEU were 
prepared and dispensed into 1536-well plates (5 µl per well; ThermoFisher) with appropriate concentrations 
of compound and controls (vehicle or 1 mM cycloheximide). Volumes were dispensed using a Multidrop 
Combi Reagent Dispenser, a Multidrop Combi nL or a Labcyte Echo® liquid handler (ThermoFisher). Plates 
were then incubated, in duplicate, at 30 °C for 25 hours prior to the addition of phosphate buffer (0.25 M, pH 
7.0, 5 µl per well) and fluorescence was read at Ex480/Em540 using a ViewLux ultraHTS Microplate Imager 
(PerkinElmer). Data were analyzed using GSK-developed Statistical Online Data Analysis Software (SODA) 
and ActivityBase (IDBS).
Leishmania axenic cell assays. As previously described36, L. donovani (MHOM/SD/62/1S-CL2D, LdBOB) 
axenic amastigotes in growth medium (6 µl) were added to a final concentration of 5.0 × 103 ml−1 with com-
pounds and controls (vehicle and assay media alone, with the robustness of the platform indicated by Z’ val-
ues > 0.5)29 in 1536-well plates (Greiner Bio-One FLUOTRAC). The plates, in at least triplicate, were incubated 
at 37 °C for 72 hours under 5% CO2. Resazurin solution was added, the plates were incubated at room temper-
ature for 4 hours and then the fluorescence read at Ex528/Em590, using an EnVision Multilabel plate reader 
(PerkinElmer). Volumes were dispensed and data analyzed as above.
From a previously described protocol22, L. major (MHOM/IL/81/Friedlin, wild type and ΔLCB2 mutant)24 were 
added to 96-well plates (Corning) at 1 × 104 ml−1 in growth media with appropriate concentrations of compounds 
and controls (vehicle and assay media alone, with the robustness of the platform indicated by Z’ values > 0.5)29 in 
100 µl. Following incubation at 26 °C for 72 hours, alamarBlue (ThermoFisher) was added, the plates were incubated 
at 26 °C for 4 or 8 hours and fluorescence was read at Ex540/Em600, using a FLx800 Fluorescence Microplate Reader 
and Gen5 1.08 Data Analysis Software (BioTek). Analyses were carried out using GraphPad Prism 7.
Mammalian cell assay. HepG2 cells in media were added (25 µl) at final concentration of 1.2 × 105 ml−1 
to 384-well plates (Greiner Bio-One FLUOTRAC) and incubated with compounds and controls (vehicle and 
cycloheximide) at 37 °C for 48 hours under 5% CO2 and at 80% relative humidity. The plates, in at least dupli-
cate, were incubated at room temperature for 30 minutes prior to the addition of CellTiter-Glo (Promega), 
followed by incubation at room temperature for 10 minutes and measurement of the luminescent output 
using a ViewLux ultraHTS Microplate Imager (PerkinElmer). Volumes were dispensed using a Multidrop 
Combi Reagent Dispenser, a Multidrop Combi nL or a Labcyte Echo liquid handler (ThermoFisher). Data 
were analyzed using GSK-developed Statistical Online Data Analysis Software (SODA) and ActivityBase 
(IDBS).
Intramacrophage Leishmania donovani assay. This protocol was based on that previously described36. 
In brief, THP-1 (human monocytic leukemia) at 6 × 105 ml−1 were infected with eGFP expressing L. dono-
vani LdBOB amastigotes at 6.0 × 106 ml−1 and incubated overnight at 37 °C. Following washing, infected cells 
were trypsinized and harvested before dispensation into a sterile 384-well plate, at 6.0 × 104 ml−1 in 50 µl 
post-differentiation growth medium with compounds and controls (vehicle and amphotericin B, with the robust-
ness of the platform indicated by Z’ values > 0.5)29. The plates, in at least duplicate, were incubated at 37 °C for 
96 hours under 5% CO2. After fixation with 4% (v/v) formaldehyde in PBS at room temperature for 30 minutes 
and washing, cells were stained with DAPI (Sigma-Aldrich) at room temperature for 30 minutes, washed, and 
imaged at Ex405/Em460 and Ex488/Em509 using the Opera® High Content Screening System (PerkinElmer). 
Volumes were dispensed as above. Images were analyzed using the automated Acapella High Content Imaging 
and Analysis Software (PerkinElmer).
Biochemical assay. Microsomal material was prepared and CHAPS washed from α ade−.lys−.leu−.Δaur1−.
pESC-LEU_ LmjFIPCS as previously described19,22. Briefly, each compound at the desired concentration was incu-
bated, in at least triplicate, in 96-well plates (Corning) in phosphate buffer (71.4 mM, pH 7.0) with PI (100 µM, 
final concentration, Avanti Polar Lipids), CHAPS (600 µM, Sigma-Aldrich) and CHAPS-washed microsomal mem-
branes (0.6 U enzyme per reaction) for 15 minutes at 30 °C. NBD-C6-ceramide (5 µM; ThermoFisher) was added, 
final volume of 40 µl per well, and the plates incubated at 30 °C for a further 25 minutes. Following quenching with 
200 µl methanol per well, the reaction product was separated using exchange chromatography in 96-well filter plates 
(Millipore)19,22 and the fluorescence measured at Ex460/Em540 using a FLx800 Fluorescence Microplate Reader and 
Gen5 1.08 Data Analysis Software (BioTek). Analyses were carried out using GraphPad Prism 7.
In cellulo IPC synthase assay. The L. major Δlcb2 mutant24, maintained in Schneider’s media 
(Sigma-Aldrich) with 15% sera (ThermoFisher), were washed and 200 µl, at 1 × 107 ml−1, incubated in serum free 
media for 60 minutes at 26 °C before the addition of 10 µM of the compounds, in at least triplicate, and further 
incubation for 18 hours. Subsequently, the reaction was initiated by the addition of BODIPY FL C5-ceramide 
complexed to BSA (1.25 µl of 0.5 mM, ThermoFisher). Following further incubation at 26 °C for 1 hour, the lipids 
were extracted by phase separation in chloroform:methanol:water (10:10:3, 200 µl) and fractionated on HTPLC 
plates, as previously18. The fluorescence was read at Ex475/Em520 using a Fuji FLA-3000 plate reader and AIDA 
Image Analyser software (version 3.52).
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